Biogen Idec Inc.'s fourth-quarter earnings missed estimates, but Wall Street barely noticed as revenue topped expectations, driven largely by steady growth in multiple sclerosis (MS) drugs Avonex (interferon beta-1a) and Tysabri (natalizumab), with investors already looking ahead to the much-anticipated launch of oral MS drug BG-12.